Publication of new and updated dose banding tables

Dear Colleague

NHS England has published eight new/updated dose banding tables on its website (NHS commissioning » Chemotherapy dose banding (england.nhs.uk)):

1. Three new tables have been uploaded into the list of documents:
• Bendamustine 45mg/mL v1
• Mogamulizumab 4mg/mL v1
• Vyxeos liposomal 2.2mg/mL and cytarabine 5mg/mL v1

2. Tables updated with new versions:
• Standard 2mg/mL v7: this table has been updated to include the new strength of arsenic trioxide (2mg/mL). There are no changes to the dose bands.
• Standard 20mg/mL v7: Irinotecan has been removed from the list of “Example drugs” as Irinotecan has its own table. There are no changes to the dose bands.
• Carfilzomib 2mg/mL v7: this table has been expanded with three additional bands. “Drug- and Dose-specific Tables” have been removed.
• Nivolumab 10mg/mL v3: the dose bands of this table have been rationalised. 220mg & 260mg dose bands have been removed (no longer needed); added additional band of 480mg. The product details have also been updated.
• Pembrolizumab 25mg/mL v3: this table has been updated to include the 6-weekly dosing.

Changes to each table are recorded on the “Amendment history” column of the document: “National dose banding table – Drug List” (link: NHS England » National dose banding table drug list). This document is updated each time a new/updated table is uploaded.

Latest News

By BOPA Executive Committee on 30th October 2026

Publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs

We are delighted to recognise the recent publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs, a new book bringing together expertise from oncology pharmacy professionals across the world.…

Read article
By BOPA Executive Committee on 30th October 2026

Acute and Supportive Oncology Clinical Consensus Statement

BOPA welcomes the Acute and Supportive Oncology Clinical Consensus Statement, to which we were pleased to contribute. It will be a benchmark for the sector, bringing direction and consistency as…

Read article
By BOPA, COSA, CAPhO & ISOPP on 13th October 2026

International Debate Webinar: Eastern and Western Medicine Can Co-exist – part of London Global Cancer Week 2026

Monday 2 November 2026 | 21:00 GMT (check your local time) Part of London Global Cancer Week 2026 Can Eastern and Western medicine co-exist in modern cancer care? Or do…

Read article
By Joseph Williams on 8th October 2026

BOPA 2026 Mentioned in Pharmaceutical Journal

Invest in aseptic services for future of specialised medicines, says chief pharmacist – The Pharmaceutical Journal Aseptic facilities are “absolutely essential” for hospitals to be involved in clinical trials and…

Read article